Company Filing History:
1 out of 110 
1 out of 140 Years Active: 2014-2018
Title: Makoto Matsuoka: Innovator in Oral Disintegrating Tablets
Introduction
Makoto Matsuoka is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral disintegrating tablets. With a total of 2 patents, Matsuoka's work focuses on improving the usability and effectiveness of medication for various populations.
Latest Patents
Matsuoka's latest patents include an innovative oral disintegrating tablet. This tablet contains D-mannitol, an active ingredient, disintegrating agents such as crospovidone and carmellose, and lubricants like sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet boasts several excellent properties, including easy production in common facilities without the need for specialized pharmaceutical techniques. It maintains appropriate strength during distribution, disintegrates quickly in the oral cavity, and offers an improved ingestion experience with reduced bitterness and gritty feel. This makes the tablet particularly suitable for aged individuals, children, and seriously ill patients.
Career Highlights
Throughout his career, Matsuoka has worked with prominent companies in the pharmaceutical industry, including Sumitomo Dainippon Pharma Co., Ltd. and Dainippon Sumitomo Pharma Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.
Collaborations
Matsuoka has collaborated with notable coworkers such as Hiroyuki Nishii and Maki Sasaki. These partnerships have likely enhanced his research and development efforts in the field of oral disintegrating tablets.
Conclusion
Makoto Matsuoka is a distinguished inventor whose work in oral disintegrating tablets has the potential to improve medication accessibility and experience for various patient demographics. His contributions to the pharmaceutical industry are noteworthy and continue to influence the development of effective dosage forms.